ACTU Insider Trading Activity and SEC Form 4 Filings
ACTU insider trading summary
Over the past 12 months, insiders at Actuate Therapeutics, Inc. (ACTU) reported 2 sales worth $3.2M by 2 insiders and 1 open-market purchase worth $50K by 1 insider on SEC Form 4. Net insider selling was $3.2M.
Latest ACTU insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Oct 28, 2026 | Daniel M Schmitt | President, CEO and Director | Buy | $50K (140,844 @ $0.35) |
| Jan 5, 2026 | Todd S Thomson | Insider | Sell | $1.6M (280,000 @ $5.80) |
| Jan 5, 2026 | Kairos Venture Partners II, L.P. | Insider | Sell | $1.6M (280,000 @ $5.80) |
| Jun 27, 2025 | Bios Actuate Co-Invest III, LP | Director | Buy | $500K (71,428 @ $7.00) |
| Jun 27, 2025 | BIOS Actuate Co-Invest I, LP | Director | Buy | $500K (71,428 @ $7.00) |
| Jun 27, 2025 | BIOS Actuate Co-Invest II, LP | Director | Buy | $500K (71,428 @ $7.00) |
| Jun 27, 2025 | BIOS Fund III QP, LP | Director | Buy | $500K (71,428 @ $7.00) |
| Jun 27, 2025 | BIOS Capital Management, LP | Director | Buy | $500K (71,428 @ $7.00) |
| Jun 27, 2025 | BIOS Fund III, LP | Director | Buy | $500K (71,428 @ $7.00) |
| Jun 27, 2025 | Aaron G.L. Fletcher | Director | Buy | $500K (71,428 @ $7.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.